Navigation Links
CryoLife's Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World
Date:9/3/2009

ATLANTA, Sept. 3 /PRNewswire-FirstCall/ -- More than 130 cardiovascular surgeons from approximately 30 countries are scheduled to attend the second annual global Ross Summit, a two-day surgical congress focused on the highly complex Ross Procedure, which is performed on up to 1,500 individuals globally each year -- a number that is expected to increase as survival data become more widely published.

CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, will convene the summit at its corporate headquarters training facility in suburban Atlanta Sept. 25-26. The forum provides an opportunity to review and discuss current peer-reviewed data from the world's experts relating to the survival advantage of the Ross Procedure and technical nuances required to perform the operation successfully.

The Ross Procedure is a type of specialized aortic valve surgery in which the patient's diseased aortic valve is replaced with his or her own pulmonary valve. The pulmonary valve can then be replaced with a cryopreserved human pulmonary valve.

Pioneered in 1967, by Mr. Donald N. Ross, FRCS in London, U.K., the procedure is a complex surgical technique that is performed by surgeons skilled in reconstructive cardiac surgery due to the level of technical expertise required to execute the procedure.

"In children, young adults and in active older adults, the Ross Procedure offers several advantages over other traditional aortic valve replacement options," said Dr. William Northrup III, vice president of physic
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ACD Completes the Second Closing of Series A Financing and Initiates Services for Biomarker Validation and Companion Diagnostic Development
2. NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
3. avVaa World Health Care Products, Inc. Announces the completion of its first week of DRTV 120/60 second test commercials for Neuroskin(R) Psoriasis Relief
4. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
5. Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing
6. Encorium Reports Second Quarter 2009 Financial Results
7. Los Gatos Research Introduces Second Generation Liquid-Water Isotope Analyzer
8. Spherix Reports Second Quarter 2009 Earnings
9. Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
10. NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
11. China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a ... Drug Administration (FDA) for the use of Medtronic,s ... (including a newly developed catheter) for use with ... intravenously to patients with pulmonary arterial hypertension.   ...
(Date:12/24/2014)... GMO corn cases filed across the ... in the process of being consolidated in a Kansas ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... District of Kansas. , Management of the Syngenta GMO ... U.S. District Judge John W. Lungstrum.* , As a ...
(Date:12/24/2014)... 23, 2014 The report ... as its definition, classification, application and industry ... manufacturing process, and product cost structure. Production ... The analysis also covers upstream raw materials, ... development trend and proposals. In the end, ...
(Date:12/24/2014)... 2014 Vermillion, Inc. (Nasdaq:   VRML), ... announced today that investors including Oracle Investment Management, ... and several Vermillion directors have agreed to purchase ... common stock and warrants to purchase unregistered shares ... Under the terms of the ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... YORK, June 18 Danube Pharmaceuticals, Inc., a,privately ... development of innovative drugs for ophthalmology, is pleased,to ... MBA as its Chief,Executive Officer., "I am ... this,inflection point in its history as it advances ...
... CHESHIRE, Conn., June 18 Alexion,Pharmaceuticals, Inc. (Nasdaq: ... Officer of Alexion Pharmaceuticals, will present at the,Jefferies & ... at 4:15,p.m., ET on Wednesday, June 25, 2008., ... available live. You can,access the webcast at: http://www.alexionpharm.com ...
... N.J., June 18 HemoCue(R) AB, a,global point-of-care ... Diagnostics Incorporated (NYSE: DGX ), today announced,that ... quantitative point-of-care,test for screening for, diagnosing and monitoring ... U.S. Food and Drug Administration (FDA). With,the FDA ...
Cached Biology Technology:Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals 2Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 2HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 4HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 5
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ... funding to expand its team and bring LaunchKey to ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
(Date:12/17/2014)... 16, 2014  Automation is fundamentally transforming the ... than at international borders. Over the past decade, ... allowed veteran travelers to self process through border ... Kiosks at an increasing number of airports, seaports, ... According to Maxine Most , Principal ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... PITTSBURGHAn international study based at the University of Pittsburgh ... can biodegrade carbon nanotubesthe superstrong materials found in products ... potentially damaging health effects of being exposed to the ... Nature Nanotechnology . The results could open the ...
... the University of Pittsburgh provides the first identification of ... materials found in products from electronics to plasticsand in ... being exposed to the tiny components, according to findings ... results could open the door to the use of ...
... leading bat expert with the USDA Forest Service,s Southern Research ... Carolina, South Carolina and Tennessee that she believes are most ... and appears to be rapidly spreading south from the northeastern ... has been confirmed in Tennessee, and she says it is ...
Cached Biology News:Pitt-led international study identifies human enzyme that breaks down potentially toxic nanomaterials, opens door to novel drug delivery 2Pitt-led international study identifies human enzyme that breaks down potentially toxic nanomaterials, opens door to novel drug delivery 3Pitt-led study identifies human enzyme that breaks down potentially toxic nanomaterials 2Pitt-led study identifies human enzyme that breaks down potentially toxic nanomaterials 3Deadly fungus threatens 9 bat species in Ga., Ky., N.C., S.C. and Tenn., expert says 2Deadly fungus threatens 9 bat species in Ga., Ky., N.C., S.C. and Tenn., expert says 3
Recombinant Mouse IL-23, CF...
... ActivePro In Vitro Translation ... E.coli lysate, synthesizes higher ... well as proteins with ... competing kits. This results ...
... , Customer Peptide Synthesis , Containing one Phospho-Amino ... mg will be returned to customer conjugation of peptide to KLH ... Maintenance 102 days/each , Pre-immune bleed ... , Test bleed (app. 5 ml) x1 ...
Donor Goat Serum...
Biology Products: